Publications

BibTex format

@article{Seferović:2019:10.1002/ejhf.1461,
author = {Seferovi, PM and Polovina, M and Bauersachs, J and Arad, M and Gal, TB and Lund, LH and Felix, SB and Arbustini, E and Caforio, ALP and Farmakis, D and Filippatos, GS and Gialafos, E and Kanjuh, V and Krljanac, G and Limongelli, G and Linhart, A and Lyon, AR and Maksimovi, R and Milii, D and Milinkovi, I and Noutsias, M and Oto, A and Oto, Ö and Pavlovi, SU and Piepoli, MF and Risti, AD and Rosano, GMC and Seggewiss, H and Aanin, M and Seferovi, JP and Ruschitzka, F and elutkiene, J and Jaarsma, T and Mueller, C and Moura, B and Hill, L and Volterrani, M and Lopatin, Y and Metra, M and Backs, J and Mullens, W and Chioncel, O and de, Boer R and Anker, S and Rapezzi, C and Coats, AJS and Tschöpe, C},
doi = {10.1002/ejhf.1461},
journal = {European Journal of Heart Failure},
pages = {553--576},
title = {Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology},
url = {http://dx.doi.org/10.1002/ejhf.1461},
volume = {21},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.
AU  - Seferovi,PM
AU  - Polovina,M
AU  - Bauersachs,J
AU  - Arad,M
AU  - Gal,TB
AU  - Lund,LH
AU  - Felix,SB
AU  - Arbustini,E
AU  - Caforio,ALP
AU  - Farmakis,D
AU  - Filippatos,GS
AU  - Gialafos,E
AU  - Kanjuh,V
AU  - Krljanac,G
AU  - Limongelli,G
AU  - Linhart,A
AU  - Lyon,AR
AU  - Maksimovi,R
AU  - Milii,D
AU  - Milinkovi,I
AU  - Noutsias,M
AU  - Oto,A
AU  - Oto,Ö
AU  - Pavlovi,SU
AU  - Piepoli,MF
AU  - Risti,AD
AU  - Rosano,GMC
AU  - Seggewiss,H
AU  - Aanin,M
AU  - Seferovi,JP
AU  - Ruschitzka,F
AU  - elutkiene,J
AU  - Jaarsma,T
AU  - Mueller,C
AU  - Moura,B
AU  - Hill,L
AU  - Volterrani,M
AU  - Lopatin,Y
AU  - Metra,M
AU  - Backs,J
AU  - Mullens,W
AU  - Chioncel,O
AU  - de,Boer R
AU  - Anker,S
AU  - Rapezzi,C
AU  - Coats,AJS
AU  - Tschöpe,C
DO  - 10.1002/ejhf.1461
EP  - 576
PY  - 2019///
SN  - 1388-9842
SP  - 553
TI  - Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology
T2  - European Journal of Heart Failure
UR  - http://dx.doi.org/10.1002/ejhf.1461
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30989768
UR  - http://hdl.handle.net/10044/1/69328
VL  - 21
ER  -

Download

DrAlexanderLyon

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)